Nuveen Asset Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

$334 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $658,225 - $1.28 Million	52,116 Added 7.45%	751,508 $17.8 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $4.35 Million - $7.06 Million	400,517 Added 134.01%	699,392 $10.4 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $2.23 Million - $3.27 Million	298,875 New	298,875 $3.27 Million
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $495,212 - $976,028	-287,914 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $14,528 - $19,091	5,245 Added 1.86%	287,914 $924,000
Q4 2021 Feb 14, 2022	SELL	$3.23 - $4.6 $74,864 - $106,618	-23,178 Reduced 7.58%	282,669 $897,000
Q3 2021 Nov 12, 2021	SELL	$3.47 - $4.42 $17,488 - $22,276	-5,040 Reduced 1.62%	305,847 $1.17 Million
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $195,782 - $244,479	-49,691 Reduced 13.78%	310,887 $1.36 Million
Q1 2021 May 17, 2021	BUY	$4.23 - $6.55 $143,257 - $221,828	33,867 Added 10.37%	360,578 $1.64 Million
Q4 2020 Feb 16, 2021	BUY	$5.73 - $9.03 $429,698 - $677,168	74,991 Added 29.79%	326,711 $1.88 Million
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $33,193 - $72,385	-9,998 Reduced 3.82%	251,720 $1.82 Million
Q2 2020 Aug 14, 2020	SELL	$1.41 - $4.25 $185,932 - $560,434	-131,867 Reduced 33.5%	261,718 $913,000
Q1 2020 May 14, 2020	SELL	$1.25 - $2.02 $487,003 - $786,998	-389,603 Reduced 49.75%	393,585 $582,000
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $599,078 - $2.67 Million	450,435 Added 135.37%	783,188 $1.54 Million
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $57,820 - $81,422	-11,293 Reduced 3.28%	332,753 $1.7 Million
Q2 2019 Aug 15, 2019	BUY	$6.05 - $13.66 $2.08 Million - $4.7 Million	344,046 New	344,046 $2.46 Million

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account